Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2019 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Income from Continuing Operations of 790155000.0 for Q1 2026, down 5283.63% year-over-year from 15243282.98 in Q1 2025, and down 13689.79% quarter-over-quarter from 5730000.0 in Q4 2025.
Powered by 
Analysis
Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 790155000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 5283.63% year-over-year to 790155000.0; the TTM figure through Mar 2026 stood at 798841000.0 (down 932.9% YoY), while the FY2025 annual figure was 23363000.0, up 73.43% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 790155000.0, down from 5730000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2905000.0 in Q3 2025, with the low at 790155000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 25279000.0 (2024), against an average of 70620000.0.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations soared 120.41% in 2025, then plunged 5283.63% in 2026.
- Mirum Pharmaceuticals' Income from Continuing Operations stood at 36431000.0 in 2022, then grew by 2.12% to 35659000.0 in 2023, then jumped by 33.28% to 23790000.0 in 2024, then surged by 75.91% to 5730000.0 in 2025, then tumbled by 13689.79% to 790155000.0 in 2026.
- Business Quant data shows MIRM's Income from Continuing Operations at 790155000.0 in Q1 2026, 5730000.0 in Q4 2025, and 2905000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Mirum Pharmaceuticals | 6.40 Bn | 5.97 Bn | 145.90 Mn | -67.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -67.23 Mn |
| Mar 31, 2026 | -790.16 Mn |
| Dec 31, 2025 | -5.73 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | -14.68 Mn |
| Dec 31, 2024 | -23.79 Mn |
| Sep 30, 2024 | -14.24 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Dec 31, 2023 | -35.66 Mn |
| Sep 30, 2023 | -23.59 Mn |
| Jun 30, 2023 | -74.04 Mn |
| Mar 31, 2023 | -30.13 Mn |
| Dec 31, 2022 | -36.43 Mn |
| Sep 30, 2022 | -35.71 Mn |
| Jun 30, 2022 | -26.92 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | 57.28 Mn |
| Sep 30, 2021 | -47.11 Mn |